These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Targeting the mu-Opioid Receptor for Cancer Treatment. Zhang H; Zhou D; Gu J; Qu M; Guo K; Chen W; Miao C Curr Oncol Rep; 2021 Aug; 23(10):111. PubMed ID: 34342720 [TBL] [Abstract][Full Text] [Related]
7. Impact of Pain, Opioids, and the Mu-opioid Receptor on Progression and Survival in Patients With Newly Diagnosed Stage IV Pancreatic Cancer. Steele GL; Dudek AZ; Gilmore GE; Richter SA; Olson DA; Eklund JP; Zylla DM Am J Clin Oncol; 2020 Aug; 43(8):591-597. PubMed ID: 32482952 [TBL] [Abstract][Full Text] [Related]
8. Opioid use in gynecologic oncology in the age of the opioid epidemic: Part I - Effective opioid use across clinical settings, a society of gynecologic oncology evidence-based review. Lefkowits C; Buss MK; Ramzan AA; Fischer S; Urban RR; Fisher CM; Duska LR Gynecol Oncol; 2018 May; 149(2):394-400. PubMed ID: 29472016 [TBL] [Abstract][Full Text] [Related]
9. Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study). Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Terashima M; Yoshida T; Sakai K; Otake Y; Koyama A; Nishio K; Nakagawa K BMC Cancer; 2017 Oct; 17(1):674. PubMed ID: 28985716 [TBL] [Abstract][Full Text] [Related]
10. A Case-Based Approach to Integrating Opioid Pharmacokinetic and Pharmacodynamic Concepts in Cancer Pain Management. Lam LH; Pirrello RD; Ma JD J Clin Pharmacol; 2016 Jul; 56(7):785-93. PubMed ID: 26626053 [TBL] [Abstract][Full Text] [Related]
11. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986 [TBL] [Abstract][Full Text] [Related]
12. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Zylla D; Gourley BL; Vang D; Jackson S; Boatman S; Lindgren B; Kuskowski MA; Le C; Gupta K; Gupta P Cancer; 2013 Dec; 119(23):4103-10. PubMed ID: 24104703 [TBL] [Abstract][Full Text] [Related]
13. Replacement of current opioid drugs focusing on MOR-related strategies. Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137 [TBL] [Abstract][Full Text] [Related]
14. Optimization of opioid utility in cancer pain populations. Wong SS; Cheung CW Ann Palliat Med; 2020 Mar; 9(2):558-570. PubMed ID: 32233627 [TBL] [Abstract][Full Text] [Related]
15. Combining opioids and non-opioids for pain management: Current status. Li JX Neuropharmacology; 2019 Nov; 158():107619. PubMed ID: 31029588 [TBL] [Abstract][Full Text] [Related]
16. Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II - Balancing safety & accessibility. Ramzan AA; Fischer S; Buss MK; Urban RR; Patsner B; Duska LR; Fisher CM; Lefkowits C Gynecol Oncol; 2018 May; 149(2):401-409. PubMed ID: 29544707 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review. Nijland L; Schmidt P; Frosch M; Wager J; Hübner-Möhler B; Drake R; Zernikow B Support Care Cancer; 2019 Jan; 27(1):33-42. PubMed ID: 30056529 [TBL] [Abstract][Full Text] [Related]
18. Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia. Oladosu FA; Conrad MS; O'Buckley SC; Rashid NU; Slade GD; Nackley AG PLoS One; 2015; 10(8):e0135711. PubMed ID: 26270813 [TBL] [Abstract][Full Text] [Related]
19. Opioids and Cancer Mortality. Amaram-Davila J; Davis M; Reddy A Curr Treat Options Oncol; 2020 Feb; 21(3):22. PubMed ID: 32095929 [TBL] [Abstract][Full Text] [Related]